Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:05:12 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:NYSE from 2023-05-07 to 2024-05-06 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-18 08:00U:NYSENews ReleaseActinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
2024-04-01 08:00U:NYSENews ReleaseActinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annua
2024-03-26 07:18U:NYSENews ReleaseActinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
2024-01-02 07:30U:NYSENews ReleaseActinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT ‚ ® and CIBMTR ‚ ®
2023-12-18 09:25U:NYSENews ReleaseHUGOTON ROYALTY TRUST DECLARES NO DECEMBER CASH DISTRIBUTION
2023-12-08 08:00U:NYSENews ReleaseActinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
2023-11-17 09:25U:NYSENews ReleaseHUGOTON ROYALTY TRUST DECLARES NO NOVEMBER CASH DISTRIBUTION
2023-11-10 11:24U:NYSENews ReleaseHigh Court of Ireland Confirms Mallinckrodt Scheme of Arrangement
2023-11-06 07:30U:NYSENews ReleaseActinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
2023-11-03 07:30U:NYSENews ReleaseActinium Appoints Lynn Bodarky as Chief Business Officer
2023-11-02 16:15U:NYSENews ReleaseActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
2023-11-02 09:05U:NYSENews ReleaseActinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
2023-10-26 09:00U:NYSENews ReleaseVicarious Surgical to Report Third Quarter 2023 Financial Results on November 13, 2023
2023-09-27 09:05U:NYSENews ReleaseActinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
2023-08-31 07:00U:NYSENews ReleaseActinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
2023-08-21 07:00U:NYSENews ReleaseActinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
2023-07-27 08:15U:NYSENews ReleaseRiskified To Report Second Quarter 2023 Financial Results on Tuesday, August 15
2023-07-24 07:00U:NYSENews ReleaseActinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
2023-07-21 09:25U:NYSENews ReleaseHUGOTON ROYALTY TRUST DECLARES NO JULY CASH DISTRIBUTION
2023-06-15 09:25U:NYSENews ReleaseInternational Association of Certified ISAOs (IACI) Deploys VirnetX Matrix and VirnetX War Room
2023-06-13 09:25U:NYSENews ReleaseVirnetX and ObjectSecurity Form a Technology Alliance Partnership to Provide Secure Cyber Vulnerability Analysis in Private Cloud Environments
2023-06-12 07:00U:NYSENews ReleaseActinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress
2023-06-09 09:25U:NYSENews ReleaseVirnetX and Envoy Sign Agreement
2023-06-07 07:00U:NYSENews ReleaseActinium Pharma Set to Join Russell 2000 ‚ ® and Russell 3000 ‚ ® Indexes
2023-05-22 07:00U:NYSENews ReleaseActinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid Cancers
2023-05-19 09:25U:NYSENews ReleaseHUGOTON ROYALTY TRUST DECLARES MAY CASH DISTRIBUTION
2023-05-09 18:45U:NYSENews ReleaseNew England Realty Associates Announces Second-Quarter Distribution on Class A Units and Depositary Receipts and an Increase to the Distribution per Quarter of $2.40 per Class A Unit or $0.08 per Depositary Receipt